Roche
divarasib
KRAS G12C non-small cell lung cancer
Resolved
5days ago
Phase 3 readout · Jul 2, 2026
What's at stake
Phase 3 trial results for divarasib in KRAS G12C non-small cell lung cancer are due Jul 2, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· Press release
verified 17h ago
“Roche announced today positive results from the phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS G12C inhibitor, against the approved, first generation KRAS G12C inhibitors.”